FDA Declines to Approve Summit Lung Cancer Drug After Trial Misses Survival Goal
The FDA declined to approve Summit Therapeutics' lung cancer drug after its trial missed a key survival goal.
The FDA declined to approve Summit Therapeutics' lung cancer drug after its trial missed a key survival goal.